Include All CSL Sites

Seqirus Leadership Team

Gordon Naylor
Brent MacGregor
Senior Vice President,
Commercial Operations
Ken Lim
Senior Vice President,
Business Services
Russell Basser
Senior Vice President,
Research & Development
Stephen Marlow
Senior Vice President,
Tanya Kennedy
Vice President,
Human Resources
Vas Mavrogenis
Vice President,
Helen Gearing
Vice President,
John Minardo 
Global Head,

Gordon Naylor - President, Seqirus

In April 2015, Gordon was appointed as President of Seqirus, CSL's global influenza business. Gordon was appointed Chief Financial Officer for parent company CSL Limited in 2010. Gordon joined CSL in 1987 and has held many operational and corporate roles in different parts of the CSL Group. Prior to the CFO role, Gordon was based in the US and responsible for CSL Behring’s global supply chain, the supply of plasma for CSL Behring and CSL’s global information systems. 

Brent MacGregor - Senior Vice President, Commercial Operations

Prior to his current role, Brent was CEO of NVS Influenza Vaccines. Over the past 12 months, Brent has led the NVS Influenza Vaccines business through a complex separation from the Novartis Vaccines & Diagnostics business, while successfully keeping the business focused as it underwent the early stages of integration with CSL. Prior to this, Brent was President of Novartis Vaccines (U.S.) and Head, Region North America. He joined Novartis in 2012 from Sanofi Pasteur, where he held a number of senior leadership roles including Managing Director, Japan; Managing Director of Australia & New Zealand and the Vice President of Influenza/Pneumo Franchise. 

Ken Lim - Senior Vice President, Business Services 

Ken is the Senior Vice President for Business Services, which includes responsibility for Strategy, Corporate Affairs, IT, Transitional Services and shared responsibility for Legal. Ken joined CSL in 2013 as Vice President, Strategic Projects. In this role, Ken focused on strategy development and the implementation of key projects for the CSL Group. Prior to joining CSL, Ken spent 13 years as an investment banker with Merrill Lynch, working for the firm in Australia, Europe and the US. While at Merrill Lynch, Ken advised CSL on a number of key strategic transactions. Ken commenced his career as a solicitor with Mallesons Stephen Jaques, a large commercial law firm in Australia, where he specialised in corporate law.

Russell Basser - Senior Vice President, Research & Development

Dr Russell Basser joined CSL in 2001 as Director of Clinical Research, Regulatory and Medical Affairs, and was based in Australia. As CSL’s late-stage clinical portfolio evolved and expanded, he led the successful design and establishment of the global Clinical R&D organisation, and relocated to King of Prussia in 2012 to lead the newly integrated global group. In 2014 he returned to Australia, and assumed the role of CSL’s Chief Medical Officer. Over the past months he has made a significant contribution leading the R&D workstream for the bioCSL-Novartis Integration team. Prior to joining CSL Russell had a distinguished career as a senior academic clinical oncologist in Australia. 

Stephen Marlow - Senior Vice President, Operations

Steve began his career with CSL in 2000. Prior to his current role of SVP / General Manager, CSL Behring Kankakee, he was the VP Operations for bioCSL, incorporating manufacturing and international commercial operations.  Steve’s other roles at CSL included increasingly more responsibility in Supply Chain and Operations and an assignment in KOP, USA in 2009, culminating in the global coordination of the rapid global response to the H1N1 pandemic event.  Steve completed his undergraduate degree in Leeds, UK and post graduate studies in business and supply chain in Melbourne, Australia. He completed his MBA in Melbourne, Australia in 2014.

Tanya Kennedy - Vice President, Human Resources

Tanya joins us from Biogen in the U.K. where over an eight-year period she held various senior-level Human Resources roles, with responsibilities covering Biogen’s European and North American operations. Prior to this, she served in specialist HR roles for a number of multinational organisations, including Compaq and Sega. 

Vas Mavrogenis - Vice President, Quality

Vas recently transitioned to his current role following his tenure as the Global Head of Quality of NVS Influenza Vaccines. Since joining Novartis in 2002, Vas has been an important part of Quality Management within the organization, particularly at the Liverpool and Siena sites, holding roles of increasing responsibility. He brings a range of industry experience to Seqirus, with previous roles at GSK and Scotia Pharmaceuticals spanning many areas of the Quality function in both local site and global roles. Vas began his career as an Analytical Development Chemist and holds a Bachelor, Masters and PhD in Biomedical Science.

Helen Gearing - Vice President, Finance
Helen recently joined Seqirus from Ernst & Young (EY) in London, where she was an Executive Director in the Life Sciences advisory practice. Before joining EY, Helen had a long and progressive career at GlaxoSmithKline in a range of finance roles, spanning Corporate, Manufacturing and Commercial divisions in both the United Kingdom and other countries. While the UK is home for Helen, she has lived in Hungary, Australia and Switzerland. She comes to Seqirus with extensive global, industry and leadership experience.

John Minardo - Global Head of Legal

Prior to his current role, John was Vice President, General Counsel & Chief Compliance Officer for NVS Influenza Vaccines. John is a highly capable and experienced commercial lawyer who, over the past 12 months, has been a critical advisor on the NVS Influenza Vaccines acquisition and integration, as well as managing the global Legal function. Prior to his current role, John was Head of Legal, providing support and advice to the North American business unit of Novartis Vaccines and Diagnostics.  John started his legal career as a litigator in New York City.  He is a qualified lawyer and attended Boston College, Brooklyn Law School and the London School of Economics.